Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
BACKGROUND
Efforts to ease administration and enhance acceptability of the oral anti-malarial artemether-lumefantrine (A-L) crushed tablet to infants and children triggered the development of a novel dispersible tablet of A-L. During early development of this new formulation, two studies were performed in healthy subjects, one to evaluate the palatability of three flavours of A-L, and a second one to compare the bioavailability of active principles between the dispersible tablet and the tablet (administered crushed and intact).


METHODS
Study 1 was performed in 48 healthy schoolchildren in Tanzania. Within 1 day, all subjects tasted a strawberry-, orange- and cherry-flavoured oral A-L suspension for 10 seconds (without swallowing) in a randomized, single-blind, crossover fashion. The palatability of each formulation was rated using a visual analogue scale (VAS). Study 2 was an open, randomized crossover trial in 48 healthy adults given single doses of A-L (80 mg artemether + 480 mg lumefantrine) with food. The objectives were to compare the bioavailability of artemether, dihydroartemisinin (DHA) and lumefantrine between the dispersible tablet and the tablet administered crushed (primary objective) and intact (secondary objective).


RESULTS
Study 1 showed no statistically significant difference in VAS scores between the three flavours but cherry had the highest score in several ratings (particularly for overall liking). Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine. Bioequivalence was also shown for peak plasma concentrations (Cmax) of DHA and lumefantrine. Compared with the intact tablet, the dispersible tablet resulted in bioequivalent lumefantrine exposure, but AUC and Cmax values of artemether and DHA were 20-35% lower.


CONCLUSIONS
Considering that cherry was the preferred flavour, and that the novel A-L dispersible tablet demonstrated similar pharmacokinetic performances to the tablet administered crushed, a cherry-flavoured A-L dispersible tablet formulation was selected for further development and testing in a large efficacy and safety study in African children with malaria.
Abdulla
Salim
S
Ifakara Health Institute, Ifakara and Dar es Salaam, Tanzania. sabdulla@ihi.or.tz
Amuri
Baraka
B
Kabanywanyi
Abdunoor M
AM
Ubben
David
D
Reynolds
Christine
C
Pascoe
Steve
S
Fitoussi
Serge
S
Yeh
Ching-Ming
CM
Nuortti
Marja
M
Séchaud
Romain
R
Kaiser
Günther
G
Lefèvre
Gilbert
G
D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001682:Biological Availability; D002648:Child; D018592:Cross-Over Studies; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005260:Female; D005421:Flavoring Agents / Q000008:administration & dosage; D005449:Fluorenes / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006805:Human Experimentation; D006801:Humans; D008297:Male; D013607:Tablets / Q000008:administration & dosage; D013636:Tanzania
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005421:Flavoring Agents; D005449:Fluorenes; D013607:Tablets; C039060:artenimol
J Clin Pharmacol. 2002 Oct;42(10):1147-58
12362930
J Med Chem. 2004 May 6;47(10):2694-9
15115411
Malar J. 2009 Oct 12;8 Suppl 1:S7
19818174
Pediatrics. 2005 Jun;115(6):e718-24
15930200
Malar J. 2009 Oct 12;8 Suppl 1:S3
19818170
Am J Trop Med Hyg. 2001 May-Jun;64(5-6):247-56
11463111
Lancet. 2008 Nov 22;372(9652):1819-27
18926569
Malar J. 2009 Oct 12;8 Suppl 1:S4
19818171
Malar J. 2009 Oct 12;8 Suppl 1:S6
19818173
Lancet. 2008 Nov 22;372(9652):1786-7
18926568
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jul 15;774(2):195-203
12076689
Antimicrob Agents Chemother. 2000 Mar;44(3):697-704
10681341
Acta Trop. 2006 Nov;100(1-2):41-53
17045558
Malar J. 2008 Nov 25;7:244
19032767
Br J Clin Pharmacol. 2002 Nov;54(5):485-92
12445027
Pharm Res. 1995 Dec;12(12):1865-8
8786957
Am J Trop Med Hyg. 2006 Jun;74(6):991-8
16760509
Trans R Soc Trop Med Hyg. 2005 Jun;99(6):459-67
15837358
Clin Pharmacokinet. 2008;47(2):91-102
18193915
Clin Pharmacokinet. 1999 Aug;37(2):105-25
10496300
Ann Pharmacother. 1996 Jun;30(6):586-8
8792942
Malar J. 2009 Oct 12;8 Suppl 1:S5
19818172
Arch Pediatr Adolesc Med. 2000 Mar;154(3):267-70
10710025